Prialt (Ziconotide) In Severe Chronic Pain

Inclusion Criteria:

• Patient is able to read, understand, and voluntarily sign the Institutional ReviewBoard (IRB) approved, written informed consent document prior to the performance ofany study-specific procedures;

• Patient must be male or female at least 18 years of age;

• Patient must have severe chronic pain for whom IT therapy is warranted;

• Patient must be willing and able to comply with the protocol, and able to maintain thePatient Daily Diary for Opioid Consumption;

• Patient must have an implanted programmable SynchroMed® Infusion System in place forthe treatment of chronic pain;

• Female patients of childbearing age agree to use adequate, appropriate contraceptivemethods. Males and their partner(s) of childbearing age must use adequate, appropriate contraceptivemethods.

Exclusion Criteria:

• Patient is pregnant or lactating;

• Patient has been on an investigational drug other than ziconotide or device within 30days prior to the initiation of the study drug;

• Patients with a known hypersensitivity (allergy) to ziconotide or any of theexcipients (other compounds) in the formulation;

• Patient has a condition that would contraindicate the use of IT analgesia, includingthe presence of infection at the microinfusion injection site (where the needle isinserted in your abdomen to fill the pump with medication), uncontrolled bleedingdiathesis (tendency for bleeding) and spinal canal obstruction that impairscirculation of Cerebral Spinal Fluid.